This is similar to retrospective data (August 2018–December 2019) from the US Flatiron Health oncology database which showed that 75% of patients with metastatic NSCLC and no EGFR or ALK mutations received immunotherapy as 1L treatment, with carboplatin + pembrolizumab + pemetrexed and carboplatin + pembrolizumab + paclitaxel being the two most common 1L regimens.4 This evidence concerns the gene ALK and non-small cell lung carcinoma.